We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

This study has been terminated.
(closed due to futility)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00524589
First Posted: September 3, 2007
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Roswell Park Cancer Institute
Results First Submitted: January 27, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Prostate Cancer
Interventions: Dietary Supplement: calcitriol
Drug: dexamethasone
Genetic: protein expression analysis
Other: laboratory biomarker analysis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Dexamethasone and Calcitriol

Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.

calcitriol: IV

dexamethasone: Oral

protein expression analysis: Correlative Study

laboratory biomarker analysis: Correlative Study


Participant Flow:   Overall Study
    Dexamethasone and Calcitriol
STARTED   18 
COMPLETED   0 
NOT COMPLETED   18 
Withdrawal by Subject                2 
Disease Progression                16 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All treated and eligible patients

Reporting Groups
  Description
Dexamethasone and Calcitriol

Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.

calcitriol: IV

dexamethasone: Oral

protein expression analysis: Correlative Study

laboratory biomarker analysis: Correlative Study


Baseline Measures
   Dexamethasone and Calcitriol 
Overall Participants Analyzed 
[Units: Participants]
 18 
Age 
[Units: Years]
Mean (Standard Deviation)
 68.2  (11.8) 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      7  38.9% 
>=65 years      11  61.1% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      0   0.0% 
Male      18 100.0% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Objective Response (Complete or Partial Response)   [ Time Frame: 1 year ]

2.  Secondary:   Corrected Serum Calcium Expression   [ Time Frame: 1 year ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Senior Administrator, Compliance - Clinical Research Services
Organization: Roswell Park Cancer Institute
phone: 716-845-2300



Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00524589     History of Changes
Other Study ID Numbers: CDR0000563197
RPCI I-65405 ( Other Identifier: Roswell Park Cancer Institute )
First Submitted: August 31, 2007
First Posted: September 3, 2007
Results First Submitted: January 27, 2014
Results First Posted: March 10, 2014
Last Update Posted: November 20, 2017